• Potent antibody drug combinations identified
• Candidate antibodies could be used to treat and protect against SARSCoV-2 infections
• Antibody combinations differentiated from others currently being investigated
New data published today by the BioIndustry Association (BIA) and Clarivate reveals that UK biotech companies raised more than £1billion in equity finance between June and August 2020, the highest quarter for investments in the sector on record.
The Health Secretary, Matt Hancock MP, has announced today in the House of Commons that the MHRA (the UK medicine regulator) will join Project Orbis, an initiative led by the USA’s Food and Drug Administration Oncology Centre of Excellence.
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “The BIA welcomes the commitment in the Bill to preserve the UK internal market, aimed at providing certainty for businesses to work and trade freely across the whole of the UK.
Biotech stocks have never been a more attractive destination for investors. As traditional sectors continue to suffer with the market disruption brought about by COVID-19, biopharma and healthcare is one of the few economic sectors to have largely escaped the global downturn.
Today the Department of Business, Energy and Industrial Strategy has awarded £100 million to fund a Cell and Gene Therapy Catapult Manufacturing Innovation Centre to accelerate production of a COVID-19 vaccine in the UK.
Steve Bates OBE, Chief Executive of the BIA said: “Antimicrobial resistance (AMR) is one of the key global challenges of our times. Despite being a global health (and BIA) policy focus for years, no market solution has yet delivered the incentives needed to make novel antibiotic development an attractive investment prospect.
Steve Bates OBE, Chief Executive of the BIA said: “It’s fantastic to see the NHS and Vertex strike a lightning quick deal to enable NHS cystic fibrosis patients to access this important breakthrough therapy.